Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Butorphanol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 known ✓ | P41145 | 17/20 | 1.00 |
| ▸ | OPRM1 known ✓ | P35372 | 13/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 14/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Butorphanol SCHEMBL20904174 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL28094979 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL19427408 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL27701479 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL16311889 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL29359664 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL10031253 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL3749 | 1.00 | OPRK1 (1.00) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL11529206 | 0.99 | OPRK1 (0.98) | OPRK1OPRD1OPRM1KCNH2 | |
| Butorphanol SCHEMBL2726244 | 0.99 | OPRK1 (0.98) | OPRK1OPRD1OPRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0061287-B1 | ANALGESIC POTENTIATION | McNeilab, Inc. (US) | 1984-08-15 | — | — | EP | claimed |
| EP-3563852-B1 | BUTORPHANOL-CONTAINING PATCH | HISAMITSU PHARMACEUTICAL CO (JP) | 2025-04-02 | — | — | EP | disclosed |
| US-11998641-B2 | Modified release coated capsules | TILLOTTS PHARMA AG (CH) | 2024-06-04 | — | — | US | disclosed |
| CN-110545816-B | Adhesive patch | 久光制药株式会社 | 2023-04-11 | — | — | CN | disclosed |
| CN-110573160-B | Adhesive patch | 久光制药株式会社 | 2022-11-18 | — | — | CN | disclosed |
| US-11266605-B2 | Modified release coated capsules | TILLOTTS PHARMA AG (CH) | 2022-03-08 | — | — | US | disclosed |
| US-20220047516-A1 | MODIFIED RELEASE COATED CAPSULES | TILLOTTS PHARMA AG (CH) | 2022-02-17 | — | — | US | disclosed |
| US-11202764-B2 | Patch | HISAMITSU PHARMACEUTICAL CO., INC. (JP) | 2021-12-21 | — | — | US | disclosed |
| CN-109071414-B | Improved process for the preparation of butorphanol tartrate | 海蔻有限公司 | 2021-11-05 | — | — | CN | disclosed |
| EP-3616699-B1 | ADHESIVE PATCH | HISAMITSU PHARMACEUTICAL CO (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-4338324-A | COMBINATION OF ZOMEPIRAC AND BUTORPHANOL | MCNEILAB, INC. (US) | 1982-07-06 | — | — | US | disclosed |
| US-4322427-A | Analgetic compositions and methods of use | BRISTOL-MYERS COMPANY (US) | 1982-03-30 | — | — | US | disclosed |
| US-4202982-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1980-05-13 | — | — | US | disclosed |
| US-4153603-A | (±)-2-Cyclobutylmethyl-9α,10β-dihydroxy-1β-(p-alkoxy-benzyl)perhydroisoquinoline | BRISTOL-MYERS COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
| US-4139534-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
| US-4139534-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1979-02-13 | — | — | US | disclosed |
| US-4115389-A | Process of N-demethylating (-)-1-(p-methoxybenzyl)-2-methyl-1,2,3,4,5,6,7,8-octahydroisoquinoline | BRISTOL-MYERS COMPANY (US) | 1978-09-19 | — | — | US | disclosed |
| US-4058531-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1977-11-15 | — | — | US | disclosed |
| US-4017497-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
| US-4017497-A | Process for the preparation of 14-hydroxymorphinan derivatives | BRISTOL-MYERS COMPANY (US) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11202764-B2 | Patch | GABBR1, GJB2, GABRB3 | OPRK1 76/4885OPRM1 47/4885OPRD1 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.